CVE:META

Meta Growth Competitors

C$0.14
0.00 (0.00 %)
(As of 11/18/2020)
Add
Compare
Today's Range
C$0.14
Now: C$0.14
C$0.14
50-Day Range
C$0.14
MA: C$0.14
C$0.14
52-Week Range
C$0.07
Now: C$0.14
C$0.18
Volume58,900 shs
Average Volume560,298 shs
Market CapitalizationC$33.14 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Meta Growth (CVE:META) Vs. LABS, KHRN, DN, NRTH, CSI, and BAMM

Should you be buying META stock or one of its competitors? Companies in the industry of "drug manufacturers—specialty & generic" are considered alternatives and competitors to Meta Growth, including MediPharm Labs (LABS), Khiron Life Sciences (KHRN), Delta 9 Cannabis (DN), 48North Cannabis (NRTH), (CSI) (CSI), and 28896 (BAMM).

Meta Growth (CVE:META) and MediPharm Labs (TSE:LABS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, analyst recommendations, dividends and risk.

Profitability

This table compares Meta Growth and MediPharm Labs' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Meta GrowthN/AN/AN/A
MediPharm LabsN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings for Meta Growth and MediPharm Labs, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Meta Growth0000N/A
MediPharm Labs02023.00

MediPharm Labs has a consensus target price of C$1.53, indicating a potential upside of 218.75%. Given MediPharm Labs' higher possible upside, analysts plainly believe MediPharm Labs is more favorable than Meta Growth.

Earnings & Valuation

This table compares Meta Growth and MediPharm Labs' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Meta GrowthC$60.96 million0.54C$-50,412,840.00C($0.21)-0.66
MediPharm LabsC$36.01 million3.44C$-123,815,040.00C($0.48)-1.00

Meta Growth has higher revenue and earnings than MediPharm Labs. MediPharm Labs is trading at a lower price-to-earnings ratio than Meta Growth, indicating that it is currently the more affordable of the two stocks.

Summary

Meta Growth beats MediPharm Labs on 4 of the 7 factors compared between the two stocks.

Khiron Life Sciences (CVE:KHRN) and Meta Growth (CVE:META) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, valuation, dividends and profitability.

Earnings and Valuation

This table compares Khiron Life Sciences and Meta Growth's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Khiron Life SciencesC$8.01 million9.37C$-39,493,921.00C($0.26)-1.90
Meta GrowthC$60.96 million0.54C$-50,412,840.00C($0.21)-0.66

Khiron Life Sciences has higher earnings, but lower revenue than Meta Growth. Khiron Life Sciences is trading at a lower price-to-earnings ratio than Meta Growth, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations for Khiron Life Sciences and Meta Growth, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Khiron Life Sciences0000N/A
Meta Growth0000N/A

Khiron Life Sciences currently has a consensus target price of C$1.20, indicating a potential upside of 140.00%. Given Khiron Life Sciences' higher probable upside, equities analysts clearly believe Khiron Life Sciences is more favorable than Meta Growth.

Profitability

This table compares Khiron Life Sciences and Meta Growth's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Khiron Life SciencesN/AN/AN/A
Meta GrowthN/AN/AN/A

Meta Growth (CVE:META) and Delta 9 Cannabis (TSE:DN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, analyst recommendations and institutional ownership.

Earnings & Valuation

This table compares Meta Growth and Delta 9 Cannabis' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Meta GrowthC$60.96 million0.54C$-50,412,840.00C($0.21)-0.66
Delta 9 CannabisC$52.05 million1.14C$-7,346,808.00C($0.07)-8.06

Delta 9 Cannabis has lower revenue, but higher earnings than Meta Growth. Delta 9 Cannabis is trading at a lower price-to-earnings ratio than Meta Growth, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Meta Growth and Delta 9 Cannabis, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Meta Growth0000N/A
Delta 9 Cannabis00014.00

Delta 9 Cannabis has a consensus target price of C$1.10, suggesting a potential upside of 89.66%. Given Delta 9 Cannabis' higher probable upside, analysts clearly believe Delta 9 Cannabis is more favorable than Meta Growth.

Profitability

This table compares Meta Growth and Delta 9 Cannabis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Meta GrowthN/AN/AN/A
Delta 9 CannabisN/AN/AN/A

Summary

Delta 9 Cannabis beats Meta Growth on 5 of the 7 factors compared between the two stocks.

48North Cannabis (CVE:NRTH) and Meta Growth (CVE:META) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

Earnings and Valuation

This table compares 48North Cannabis and Meta Growth's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
48North CannabisC$17.36 million1.95C$-52,460,873.00C($0.26)-0.65
Meta GrowthC$60.96 million0.54C$-50,412,840.00C($0.21)-0.66

Meta Growth has higher revenue and earnings than 48North Cannabis. Meta Growth is trading at a lower price-to-earnings ratio than 48North Cannabis, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares 48North Cannabis and Meta Growth's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
48North CannabisN/AN/AN/A
Meta GrowthN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for 48North Cannabis and Meta Growth, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
48North Cannabis0000N/A
Meta Growth0000N/A

Summary

Meta Growth beats 48North Cannabis on 3 of the 5 factors compared between the two stocks.

(CSI) (CNSX:CSI) and Meta Growth (CVE:META) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, valuation, profitability, institutional ownership, risk and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings and target prices for (CSI) and Meta Growth, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
(CSI)0000N/A
Meta Growth0000N/A

Profitability

This table compares (CSI) and Meta Growth's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
(CSI)N/AN/AN/A
Meta GrowthN/AN/AN/A

Valuation & Earnings

This table compares (CSI) and Meta Growth's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
(CSI)N/AN/AN/AN/AN/A
Meta GrowthC$60.96 million0.54C$-50,412,840.00C($0.21)-0.66

(CSI) has higher earnings, but lower revenue than Meta Growth.

Summary

Meta Growth beats (CSI) on 1 of the 1 factors compared between the two stocks.

28896 (CNSX:BAMM) and Meta Growth (CVE:META) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, analyst recommendations, valuation and risk.

Earnings and Valuation

This table compares 28896 and Meta Growth's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
28896N/AN/AN/AN/AN/A
Meta GrowthC$60.96 million0.54C$-50,412,840.00C($0.21)-0.66

28896 has higher earnings, but lower revenue than Meta Growth.

Analyst Ratings

This is a breakdown of current recommendations and price targets for 28896 and Meta Growth, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
288960000N/A
Meta Growth0000N/A

Profitability

This table compares 28896 and Meta Growth's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
28896N/AN/AN/A
Meta GrowthN/AN/AN/A

Summary

Meta Growth beats 28896 on 1 of the 1 factors compared between the two stocks.


Meta Growth Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
LABS
MediPharm Labs
1.4$0.48flatC$123.82 millionC$36.01 million-1.00
KHRN
Khiron Life Sciences
0.9$0.50flatC$67.34 millionC$8.01 million-1.90
DN
Delta 9 Cannabis
1.4$0.58flatC$59.18 millionC$52.05 million-8.06News Coverage
NRTH
48North Cannabis
0.7$0.17flatC$36.44 millionC$17.36 million-0.65High Trading Volume
CSI
(CSI)
0.6N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
BAMM
28896
0.5N/AN/A$0.00N/A0.00High Trading Volume
ATT
Abattis Bioceuticals
0.5N/AN/AC$0.00N/A0.00Gap Down
AGRA
Agraflora Organics International
1.4N/AN/A$0.00N/A0.00High Trading Volume
GRIN
Grindrod Shipping
1.7N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
IMCC
IM Cannabis
0.0N/AN/A$0.00N/A0.00High Trading Volume
PULL
Mind Cure Health
1.7N/AN/A$0.00N/A0.00High Trading Volume
SPR
Spirit AeroSystems
0.5N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
BUZZ
VanEck Vectors Social Sentiment ETF
1.0N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
VIDA
Vidaroo
0.5N/AN/A$0.00N/A0.00High Trading Volume
This page was last updated on 4/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.